Concepts (149)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 15 | 2024 | 4966 | 1.040 |
Why?
|
| Glioblastoma | 10 | 2024 | 1776 | 0.940 |
Why?
|
| Meningeal Neoplasms | 4 | 2024 | 473 | 0.540 |
Why?
|
| Oncologists | 2 | 2023 | 136 | 0.360 |
Why?
|
| Burnout, Professional | 2 | 2023 | 224 | 0.300 |
Why?
|
| Meningeal Carcinomatosis | 2 | 2024 | 33 | 0.270 |
Why?
|
| Radiation Injuries | 1 | 2014 | 1475 | 0.260 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 1173 | 0.260 |
Why?
|
| DNA Modification Methylases | 1 | 2024 | 176 | 0.230 |
Why?
|
| Pregnancy, Twin | 2 | 2015 | 171 | 0.230 |
Why?
|
| DNA Repair Enzymes | 1 | 2024 | 238 | 0.220 |
Why?
|
| Tumor Microenvironment | 5 | 2021 | 3041 | 0.220 |
Why?
|
| Psychological Tests | 1 | 2023 | 137 | 0.210 |
Why?
|
| Bevacizumab | 2 | 2016 | 967 | 0.200 |
Why?
|
| Benzimidazoles | 1 | 2024 | 437 | 0.190 |
Why?
|
| Astrocytoma | 1 | 2024 | 325 | 0.190 |
Why?
|
| Glioma | 2 | 2022 | 1986 | 0.180 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2020 | 1852 | 0.170 |
Why?
|
| Job Satisfaction | 1 | 2020 | 122 | 0.170 |
Why?
|
| Viral Matrix Proteins | 1 | 2020 | 179 | 0.160 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2024 | 522 | 0.160 |
Why?
|
| Mefloquine | 1 | 2018 | 10 | 0.160 |
Why?
|
| Memantine | 1 | 2018 | 50 | 0.160 |
Why?
|
| Antineoplastic Agents | 2 | 2017 | 14636 | 0.150 |
Why?
|
| Terminal Care | 1 | 2021 | 466 | 0.140 |
Why?
|
| Lomustine | 1 | 2016 | 42 | 0.140 |
Why?
|
| Cytomegalovirus Infections | 1 | 2020 | 495 | 0.130 |
Why?
|
| Symptom Assessment | 1 | 2018 | 271 | 0.130 |
Why?
|
| Lung Neoplasms | 4 | 2024 | 12040 | 0.130 |
Why?
|
| Metformin | 1 | 2018 | 397 | 0.120 |
Why?
|
| Diseases in Twins | 1 | 2015 | 111 | 0.120 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2019 | 1020 | 0.120 |
Why?
|
| Humans | 29 | 2024 | 271093 | 0.110 |
Why?
|
| Public Health | 1 | 2016 | 296 | 0.110 |
Why?
|
| Melanoma | 2 | 2023 | 5597 | 0.110 |
Why?
|
| Drug Delivery Systems | 1 | 2017 | 662 | 0.110 |
Why?
|
| Cancer Pain | 1 | 2018 | 345 | 0.100 |
Why?
|
| Ultrasonography, Prenatal | 2 | 2015 | 923 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 1658 | 0.100 |
Why?
|
| Prenatal Care | 1 | 2015 | 348 | 0.100 |
Why?
|
| Digital Rectal Examination | 1 | 2012 | 14 | 0.100 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 1095 | 0.100 |
Why?
|
| Necrosis | 1 | 2014 | 593 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 16720 | 0.100 |
Why?
|
| Pregnancy Outcome | 1 | 2015 | 684 | 0.100 |
Why?
|
| Disease Progression | 3 | 2022 | 6868 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2015 | 646 | 0.090 |
Why?
|
| Middle Aged | 15 | 2024 | 90524 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 3416 | 0.090 |
Why?
|
| Wound Healing | 1 | 2015 | 770 | 0.090 |
Why?
|
| Female | 19 | 2024 | 149120 | 0.090 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 1338 | 0.080 |
Why?
|
| Adult | 12 | 2024 | 82174 | 0.080 |
Why?
|
| Male | 16 | 2024 | 128484 | 0.080 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 5317 | 0.080 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2015 | 1270 | 0.080 |
Why?
|
| Prostate-Specific Antigen | 1 | 2012 | 1029 | 0.070 |
Why?
|
| Aged | 11 | 2024 | 73550 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 2395 | 0.070 |
Why?
|
| Smoking | 1 | 2016 | 2555 | 0.070 |
Why?
|
| Consensus | 2 | 2024 | 1112 | 0.060 |
Why?
|
| Twinning, Monozygotic | 2 | 2015 | 2 | 0.060 |
Why?
|
| Chorion | 2 | 2015 | 14 | 0.060 |
Why?
|
| Treatment Outcome | 6 | 2024 | 33808 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2019 | 10400 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2017 | 3559 | 0.060 |
Why?
|
| Early Detection of Cancer | 1 | 2012 | 1344 | 0.050 |
Why?
|
| Mass Screening | 1 | 2012 | 1554 | 0.050 |
Why?
|
| Tyrphostins | 1 | 2022 | 110 | 0.050 |
Why?
|
| Young Adult | 5 | 2019 | 22293 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2024 | 31079 | 0.050 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2019 | 4006 | 0.050 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2024 | 557 | 0.040 |
Why?
|
| Research Design | 2 | 2018 | 1570 | 0.040 |
Why?
|
| Steroids | 1 | 2021 | 372 | 0.040 |
Why?
|
| Leukapheresis | 1 | 2020 | 166 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2024 | 16238 | 0.040 |
Why?
|
| Survival Rate | 3 | 2019 | 12535 | 0.040 |
Why?
|
| Blood-Brain Barrier | 1 | 2020 | 251 | 0.040 |
Why?
|
| Self Report | 1 | 2023 | 798 | 0.040 |
Why?
|
| Lymphocyte Depletion | 1 | 2020 | 316 | 0.040 |
Why?
|
| Disease Management | 1 | 2024 | 1092 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2024 | 1320 | 0.040 |
Why?
|
| Universities | 1 | 2019 | 161 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 1 | 2021 | 354 | 0.040 |
Why?
|
| Ipilimumab | 1 | 2023 | 765 | 0.040 |
Why?
|
| Texas | 2 | 2019 | 6452 | 0.040 |
Why?
|
| Neoplasms | 2 | 2024 | 15933 | 0.040 |
Why?
|
| Cytomegalovirus | 1 | 2020 | 496 | 0.040 |
Why?
|
| Astrocytes | 1 | 2020 | 406 | 0.030 |
Why?
|
| Epitopes | 1 | 2019 | 705 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 1824 | 0.030 |
Why?
|
| Adolescent | 4 | 2019 | 32784 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 5938 | 0.030 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2024 | 1900 | 0.030 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 15282 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2016 | 174 | 0.030 |
Why?
|
| Retrospective Studies | 4 | 2024 | 39951 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2024 | 1463 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2018 | 694 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2022 | 1132 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 1329 | 0.030 |
Why?
|
| Pyridines | 1 | 2022 | 1313 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 2067 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2012 | 5867 | 0.030 |
Why?
|
| Fetal Therapies | 1 | 2015 | 74 | 0.030 |
Why?
|
| Fetal Heart | 1 | 2015 | 112 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2024 | 2770 | 0.030 |
Why?
|
| Polycythemia | 1 | 2015 | 65 | 0.030 |
Why?
|
| Middle Cerebral Artery | 1 | 2015 | 113 | 0.030 |
Why?
|
| Neurosurgical Procedures | 1 | 2019 | 634 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2015 | 267 | 0.030 |
Why?
|
| Macrophages | 1 | 2020 | 1333 | 0.030 |
Why?
|
| United States | 2 | 2024 | 15891 | 0.030 |
Why?
|
| Risk Factors | 2 | 2021 | 17911 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2022 | 7900 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 2272 | 0.030 |
Why?
|
| Fetal Growth Retardation | 1 | 2015 | 232 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2012 | 10714 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2019 | 1581 | 0.030 |
Why?
|
| Fetofetal Transfusion | 1 | 2015 | 187 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 3412 | 0.030 |
Why?
|
| Palliative Care | 1 | 2024 | 2175 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2012 | 86 | 0.020 |
Why?
|
| Congenital Abnormalities | 1 | 2015 | 280 | 0.020 |
Why?
|
| Pregnancy | 2 | 2015 | 8131 | 0.020 |
Why?
|
| Mutation | 2 | 2024 | 15904 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 2051 | 0.020 |
Why?
|
| Gene Expression | 1 | 2018 | 3606 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 6258 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2021 | 6780 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 3846 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2016 | 1234 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2015 | 854 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 5056 | 0.020 |
Why?
|
| Time Factors | 1 | 2021 | 12991 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 1937 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 9039 | 0.020 |
Why?
|
| Child | 2 | 2019 | 30596 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 3953 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 5238 | 0.020 |
Why?
|
| Comorbidity | 1 | 2012 | 2394 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2019 | 17095 | 0.010 |
Why?
|
| Age Factors | 1 | 2012 | 5458 | 0.010 |
Why?
|
| Incidence | 1 | 2012 | 5841 | 0.010 |
Why?
|
| Prognosis | 1 | 2019 | 22529 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 3707 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 2012 | 4796 | 0.010 |
Why?
|
| Animals | 1 | 2020 | 61554 | 0.010 |
Why?
|